awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q58695709-301CD8E0-8E6B-4118-B3E7-F76654CAEE66
Q58695709-301CD8E0-8E6B-4118-B3E7-F76654CAEE66
BestRank
Statement
http://www.wikidata.org/entity/statement/Q58695709-301CD8E0-8E6B-4118-B3E7-F76654CAEE66
Interconversion of two commonly used performance tools: An analysis of 5844 paired assessments in 1501 lung cancer patients
P2860
Q58695709-301CD8E0-8E6B-4118-B3E7-F76654CAEE66
BestRank
Statement
http://www.wikidata.org/entity/statement/Q58695709-301CD8E0-8E6B-4118-B3E7-F76654CAEE66
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
454760b925d44c9296798087f57331b480743b8b
P2860
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.